Related Experiment Videos
Arrhythmia and hypertrophic cardiomyopathy
C F Shakespeare1, P J Keeling, A K Slade
1Department of Cardiological Sciences, St. George's Hospital, Medical School, London, England.
Insights
Atrial fibrillation is common in hypertrophic cardiomyopathy, worsening symptoms. Arrhythmias and autonomic dysfunction can lead to sudden cardiac death in these patients.
Area of Science:
- Cardiology
- Cardiac Electrophysiology
- Hypertrophic Cardiomyopathy
Background:
- Atrial fibrillation is the most frequent arrhythmia in hypertrophic cardiomyopathy (HCM).
- This arrhythmia is linked to rapid symptom worsening in HCM patients.
- Non-sustained ventricular tachycardia (NSVT) affects 20% of HCM patients and predicts sudden death.
Purpose of the Study:
- To review the role of arrhythmias in hypertrophic cardiomyopathy.
- To discuss the mechanisms of sudden cardiac death in HCM.
- To outline current therapeutic strategies for arrhythmias in HCM.
Main Methods:
- Literature review of studies on arrhythmias in hypertrophic cardiomyopathy.
- Analysis of the relationship between arrhythmias and sudden cardiac death.
- Discussion of pharmacological management of atrial fibrillation and ventricular arrhythmias.
Main Results:
- Atrial fibrillation is a common and serious complication in HCM.
- Non-sustained ventricular tachycardia is a significant predictor of sudden cardiac death in adults with HCM.
- The proposed mechanism of sudden death involves initiating factors like arrhythmia and autonomic dysfunction, leading to hemodynamic instability and myocardial ischemia.
Conclusions:
- Arrhythmias, particularly atrial fibrillation and ventricular tachycardia, are critical concerns in HCM management.
- Understanding the mechanisms of sudden death is crucial for risk stratification and prevention.
- Appropriate pharmacological interventions are essential for managing arrhythmias and reducing mortality in HCM.
Abstract:
Atrial fibrillation is the commonest arrhythmia observed in hypertrophic cardiomyopathy, and is associated with an acute deterioration in symptoms. Digoxin is the drug of choice in established atrial fibrillation and amiodarone the drug of choice in paroxysmal atrial fibrillation and ventricular arrhythmia. Non-sustained ventricular tachycardia occurs in 20% of patients and is the single best predictor of sudden death in adults. Sustained monomorphic ventricular tachycardia occurs only rarely. The mechanism of sudden death is likely to involve initiating factors such as arrhythmia and peripheral autonomic dysfunction causing haemodynamic instability and myocardial ischaemia. Myocardial disarray may provide the arrhythmogenic substrate such that haemodynamic instability and ischaemia results in ventricular fibrillation and sudden death.